Free Newsletter
Novartis' Gorsky to return to J&J
Free newsletter via e-mail
Tools
Well, we didn't have to watch Alex Gorsky (photo) for long. According to the Wall Street Journal, when Novartis said that the U.S. pharma CEO was leaving, they left out the part about his returning to alma mater Johnson & Johnson. Gorsky will be chairman of Ethicon, a J&J unit that makes surgical equipment and sutures. Gorsky left J&J to join Novartis in 2004.
Novartis also told the WSJ that Gorsky's exit had nothing to do with any of the changes new worldwide pharma chief Joe Jiminez is making at the company.
- check out the story in the Wall Street Journal
Related Articles:
U.S. CEO exits Novartis. Report
CEO: Novartis plans big restructuring. Report
Lagging sales spur Novartis layoffs. Report
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact
